fficacy and Safety of Bosutinib Vs Imatinib By Charlson Comorbidity Index in Newly Diagnosed Patients with Chronic Myeloid Leukemia

被引：0
|
作者：
Deininger, Michael W. [1 ]
Brummendorf, Tim H. [2 ,3 ]
Lipton, Jeffrey H. [4 ]
Milojkovic, Dragana [5 ]
Stenke, Leif [6 ,7 ]
Leip, Eric [9 ]
Purcell, Simon [8 ,10 ]
Viqueira, Andrea [11 ]
Cortes, Jorge E. [12 ]
机构：
[1] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA
[2] Univ Med Ctr Aachen, Dept Internal Med 4, Aachen, Germany
[3] Univ Klinikum RWTH Aachen, Med Klin 4, Aachen, Germany
[4] Princess Margaret Canc Ctr, Hans Messner Allogene Blood & Marrow Transplant U, Toronto, ON, Canada
[5] Imperial Coll NHS Trust, Hammersmith Hosp, Dept Haematol, London, England
[6] Karolinska Univ Hosp, Dept Hematol, Theme Canc, Stockholm, Sweden
[7] Karolinska Univ Hosp, Dept Med Solna, Stockholm, Sweden
[8] Karolinska Inst, Stockholm, Sweden
[9] Pfizer Inc, Cambridge, MA USA
[10] Pfizer Ltd, London, England
[11] Pfizer SLU, Madrid, Spain
[12] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-163276
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3913 / 3915
页数：3
相关论文
共 50 条
  • [1] Outcomes with bosutinib vs. imatinib by Charlson Comorbidity Index in patients with chronic myeloid leukaemia
    Shay, Gemma
    Deininger, Michael W.
    Bruemmendorf, Tim H.
    Lipton, Jeffrey H.
    Stenke, Leif
    Leip, Eric
    Purcell, Simon
    Viqueira, Andrea
    Cortes, Jorge E.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 96 - 97
  • [2] The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia.
    Brummendorf, Tim H.
    Cortes, Jorge E.
    Busque, Lambert
    Gambacorti-Passerini, Carlo
    Stenke, Leif
    Viqueira, Andrea
    Leip, Eric
    Purcell, Simon
    Deininger, Michael W.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Cardiac, Vascular and Hypertension Safety of Bosutinib vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial
    Cortes, Jorge E.
    Bruemmendorf, Tim H.
    Gambacorti-Passerini, Carlo
    Clark, Richard
    Leip, Eric
    Viqueira, Andrea
    Kota, Vamsi
    Deininger, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S294 - S295
  • [4] BOSUTINIB VS IMATINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: INITIAL RESULTS FROM THE BFORE TRIAL
    Bruemmendorf, T. H.
    Gambacorti-Passerini, C.
    Deininger, M.
    Mauro, M. J.
    Chuah, C.
    Kim, D. W.
    Reilly, L.
    Jeynes-Ellis, A.
    Leip, E.
    Bardy-Bouxin, N.
    Hochhaus, A.
    Cortes, J. E.
    HAEMATOLOGICA, 2017, 102 : 152 - 152
  • [5] Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial
    Deininger, Michael W.
    Kota, Vamsi
    Lipton, Jeff H.
    Milojkovic, Dragana
    Garcia Gutierrez, Valentin
    Leip, Eric
    Nick, Sonja
    Hochhaus, Andreas
    Gambacorti-Passerini, Carlo
    Cortes, Jorge E.
    Brummendorf, Tim H.
    BLOOD, 2018, 132
  • [6] Safety and Management of Toxicities in the BELA Trial of Bosutinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
    Gambacorti-Passerini, Carlo
    Cortes, Jorge E.
    Harris, Patricia
    Powell, Christine
    Countouriotis, Athena
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 732 - 732
  • [7] Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
    Gambacorti-Passerini, Carlo
    Cortes, Jorge E.
    Lipton, Jeff H.
    Dmoszynska, Anna
    Wong, Raymond S.
    Rossiev, Victor
    Pavlov, Dmitri
    Marchant, Karin Gogat
    Duvillie, Ladan
    Khattry, Navin
    Kantarjian, Hagop M.
    Bruemmendorf, Tim H.
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (10) : 947 - 953
  • [8] Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study
    Gambacorti-Passerini, Carlo
    Bruemmendorf, Tim H.
    Gjertsen, Bjorn T.
    Abboud, Camille
    Rosti, Gianantonio
    Abruzzese, Elisabetta
    Leip, Eric
    Viqueira, Andrea
    Garcia Gutierrez, Valentin
    Giles, Frank
    Hochhaus, Andreas
    BLOOD, 2019, 134
  • [9] Efficacy and safety of bosutinib by charlson comorbidity index in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study
    Gambacorti-Passerini, C.
    Bruemmendorf, T. H.
    Gjertsen, T.
    Abboud, C.
    Rosti, G.
    Abruzzese, E.
    Leip, E.
    Viqueira, A.
    Garcia-Gutierrez, V.
    Giles, F.
    Castagnetti, F.
    Hochhaus, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 79 - 80
  • [10] Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial.
    Cortes, Jorge E.
    Brummendorf, Tim H.
    Gambacorti-Passerini, Carlo
    Clark, Richard E.
    Leip, Eric
    Viqueira, Andrea
    Kota, Vamsi
    Deininger, Michael W. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345